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A B S T R A C T   
Objectives: Radiological characteristics and radiomics signatures can aid in differentiation between small cell lung 
carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). We investigated whether molecular subtypes of 
large cell neuroendocrine carcinoma (LCNEC), i.e. SCLC-like (with pRb loss) vs. NSCLC-like (with pRb expres-
sion), can be distinguished by imaging based on (1) imaging interpretation, (2) semantic features, and/or (3) a 
radiomics signature, designed to differentiate between SCLC and NSCLC. 
Materials and Methods: Pulmonary oncologists and chest radiologists assessed chest CT-scans of 44 LCNEC pa-
tients for ‘small cell-like’ or ‘non-small cell-like’ appearance. The radiologists also scored semantic features of 50 
LCNEC scans. Finally, a radiomics signature was trained on a dataset containing 48 SCLC and 76 NSCLC 
scans and validated on an external set of 58 SCLC and 40 NSCLC scans. This signature was applied on scans of 28 
SCLC-like and 8 NSCLC-like LCNEC patients. 
Results: Pulmonary oncologists and radiologists were unable to differentiate between molecular subtypes of 
LCNEC and no significant differences in semantic features were found. The area under the receiver operating 
characteristics curve of the radiomics signature in the validation set (SCLC vs. NSCLC) was 0.84 (95% confidence 
interval (CI) 0.77-0.92) and 0.58 (95% CI 0.29-0.86) in the LCNEC dataset (SCLC-like vs. NSCLC-like). 
Conclusion: LCNEC appears to have radiological characteristics of both SCLC and NSCLC, irrespective of pRb loss, 
compatible with the SCLC-like subtype. Imaging interpretation, semantic features and our radiomics signature 
designed to differentiate between SCLC and NSCLC were unable to separate molecular LCNEC subtypes, which 
underscores that LCNEC is a unique disease.   
1. Introduction 
Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare 
tumor type, representing 1-3% of all types of lung cancer [1,2]. The 
histological diagnosis of LCNEC is complex, and preferably, surgical 
resected tumor tissue is used [3]. LCNEC can be separated in two main 
molecular subtypes: the first is SCLC-like (pathological SCLC-like, 
pSCLC-like), with co-mutation of RB1 and TP53 and loss of immuno-
histochemical (IHC) pRb expression and the second is NSCLC-like 
(pNSCLC-like), with co-mutation of TP53 and STK11/KEAP1/KRAS 
genes and preserved pRb expression [4–6]. These subtypes might be 
predictive for chemotherapeutic responses [6,7]. 
Over the past years efforts have been made to differentiate between 
the two main lung cancer subtypes, small cell lung carcinoma (SCLC) 
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and non-small cell lung carcinoma (NSCLC), based on semantic features 
and radiomics signatures of routinely performed diagnostic chest CT- 
scans [8,9]. Classic SCLC is described most commonly as a bulky cen-
tral mass with major mediastinal lymph node involvement, whereas 
NSCLC is often located peripherally in the lungs with less extensive 
nodal involvement [3]. In small case series almost exclusively consisting 
of stage I-III LCNEC, 0-36% of the tumors were located centrally 
[10–15]. 
In this study we performed an in-depth analysis of CT-scans obtained 
in daily clinical practice to answer the following questions: 1) Are pul-
monary oncologists and chest radiologists able to identify pSCLC-like 
and pNSCLC-like LCNEC based on their interpretation of radiological 
images? 2) Are there semantic features associated with molecular 
LCNEC subtypes and do the LCNEC subtypes resemble SCLC and NSCLC? 
Radiomics combines quantitative imaging features that can be extracted 
from standard-of-care medical imaging into so-called signatures [16, 
17]. Therefore, we finally investigated 3) whether we could classify 
SCLC and NSCLC based on a radiomics signature and if we could use this 
signature to identify pSCLC-like and pNSCLC-like LCNEC, under the 
hypothesis that pSCLC-like LCNEC has comparable radiological char-
acteristics as SCLC and pNSCLC-like LCNEC as NSCLC. 
2. Material and Methods 
2.1. Patient selection 
Diagnostic pretreatment CT-scans were requested for 158 patients 
with a confirmed LCNEC diagnosis after pathological review (Supple-
mental figure A) [6]. IHC pRb (13A10) staining was performed on 
available formalin fixed paraffin embedded tissue, as described 
previously [6]. Baseline CT-scans of 127 stage IV SCLC patients and 138 
stage IV NSCLC patients were added to the study population (Supple-
mental figure B) [18]. 
The study protocol was approved by the medical ethical committee 
of the Maastricht UMC (METC azM/UM 14-4-043) and patient 
informed consent was waived due to the retrospective and anonymous 
nature of the study. 
2.2. Imaging interpretation 
A digital survey was developed with representative 2D images of CT- 
scans of LCNEC patients, from whom IHC pRb status was available 
(N  44) to evaluate the imaging interpretation by pulmonary oncolo-
gists (Qualtrics XM) (Supplemental figure C). Ten CT-scans of both SCLC 
and NSCLC patients were randomly included as controls (Supplemental 
figure A). The survey was distributed among all Dutch pulmonary on-
cologists, but only answers of clinicians with at least five years’ expe-
rience were included in the analysis. Participants were asked to score for 
each CT-scan whether their first impression would be ‘small cell’, ‘non- 
small cell’ or ‘not determinable based on the radiological image’ and a 
‘combination score’ was constructed for each scan (Supplemental 
methods A and B). Positive predictive values (PPVs) were calculated for 
imaging SCLC-like (iSCLC-like) and imaging NSCLC-like (iNSCLC-like) 
survey outcomes and association of molecular subtypes with survey 
outcome was investigated using the Fisher’s exact test. A p-value <0.05 
was considered significant. 
2.3. Semantic features 
To evaluate semantic features, next to the CT-scans used in the 
Fig. 1. Individual results of survey among 23 pulmonary oncologists (A) and 3 chest radiologists (B). Each column represents a CT-scan and each row represents a 
pulmonary oncologist or radiologist. The last row shows the combined score (iSCLC-like: 50% scored as small cell-like and none as non-small cell-like, iNSCLC-like: 
50% scored as non-small cell-like and none as small cell-like, No consensus: all other cases). Abbreviations: SCLC  small cell lung carcinoma, NSCLC  non-small 
cell lung carcinoma, LCNEC  large cell neuroendocrine carcinoma, pSCLC-like  pathological SCLC-like, pNSCLC-like  pathological NSCLC-like. 
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survey, additional scans of LCNEC patients with unknown IHC pRb 
status were included. Patients with missing slices of their CT-scan and 
those without a clear intrathoracic tumor were excluded (Supplemental 
figure A). Three experienced and dedicated chest radiologists (RC, FMH, 
HG) read the scans for semantic features (LCNEC N  50, SCLC N  10, 
NSCLC N  10) and a ‘combination score’ was constructed for each 
feature (Supplemental methods B, Supplemental figure D). Association 
of semantic features with pathological diagnosis was tested with the 
Fisher’s exact test for cases with known IHC pRb status (LCNEC N  38). 
Furthermore, the radiologists were asked to interpret the CT-scans in 
analogy to the pulmonary oncologists. 
2.4. Radiomics signature 
For evaluation of quantitative imaging features, additional scans 
from SCLC and NSCLC patients were added to the LCNEC and control 
scans used in the previous parts of this study (Supplemental figure B). 
The primary gross tumor volume of all scans was delineated by two 
investigators (SS and BH), supervised and checked by HG. Non- 
diagnostic CT-scans, including non-contrast enhanced CT-scans and 
scans without a well delimited intrapulmonary primary tumor were 
excluded. Furthermore, some scans had to be excluded due to technical 
problems with feature extraction (mostly variable slice spacing). The 
dataset was divided in a training set (SCLC (N  48) and NSCLC 
(N  76)) and external validation set (validation set 1, SCLC (N  58) 
and NSCLC (N  40)). The resulting signature was applied to the dataset 
of LCNEC cases (validation set 2, pSCLC-like (N  28) and pNSCLC-like 
(N  8) LCNEC) (Supplemental figure B). CT-image pre-processing, 
radiomics feature extraction, and feature harmonization are described 
extensively in Supplemental methods C. 
3. Results 
3.1. Imaging interpretation 
The survey results of 23 pulmonary oncologists were used for anal-
ysis (Fig. 1A). In the control group, the 2 patients by consensus allocated 
as iSCLC-like, were indeed SCLC (PPV 100%), and 7/8 patients allocated 
as iNSCLC-like were NSCLC (PPV 88%). In the LCNEC group, 1/44 was 
classified as iSCLC-like and 19/34 were classified as iNSCLC-like. The 
only LCNEC allocated as iSCLC-like was also pSCLC-like (PPV 100%). 
However, out of 19 patients regarded as iNSCLC-like, only 4 were 
pNSCLC-like, resulting in a PPV of 21% for an iNSCLC-like test being 
pNSCLC-like (Fig. 1A, Supplemental table A). 
The radiologists also scored 2 SCLCs as iSCLC-like (PPV 100%), while 
only 6/9 iNSCLC-like scored cases represented NSCLC (PPV 66%). In the 
LCNEC group, 2/38 were allocated to the iSCLC-like group and 8/38 to 
the iNSCLC-like group. The PPV of an iSCLC-like scan to be a pSCLC-like 
LCNEC was 100% (2/2), but PPV of an iNSCLC-like scan to be pNSCLC- 
like LCNEC was only 13% (1/8) (Fig. 1B, Supplemental table A). 
3.2. Semantic features 
An overview of all semantic features for 50 stage IV LCNEC is pro-
vided in Table 1. A peripheral location was more common than a central 
location (20/50 (40%) vs. 9/50 (18%)), while in 21 cases location was 
not determinable/no consensus (42%). In the control group, SCLC was 
more often located centrally compared to NSCLC (3/10 vs. 0/10, 
p  0.040). No significant differences were observed in semantic fea-
tures between 1) pSCLC-like and pNSCLC-like LCNEC and 2) other fea-
tures of SCLC and NSCLC (Fig. 2, Supplemental table B). 
3.3. Radiomics signature 
A dataset of scans of SCLC and NSCLC patients was used to train a 
random forest model to separate both tumor types (Supplemental figure 
Table 1 
Semantic features of CT-scans of patients with stage IV large cell neuroendocrine 
carcinoma (N  50).   
LCNEC 
N (%) 
Total number of patients 50 
Tumor location  
Central 9 (18) 
Peripheral 20 (40) 
ND 4 (8) 
NC 17 (34) 
Involved lung lobe  
LLL 4 (8) 
LUL 22 (44) 
RLL 5 (10) 
RML 0 (0) 
RUL 14 (28) 
ND 4 (8) 
NC 1 (2) 
Tumor size  
<3cm 10 (20) 
3-7cm 20 (40) 
>7cm 13 (26) 
ND 6 (12) 
NC 1 (2) 
T  
T0 7 (14) 
T1 6 (12) 
T2 10 (20) 
T3 19 (38) 
T4 0 (0) 
ND 3 (6) 
NC 5 (10) 
N  
N0 4 (8) 
N1 2 (4) 
N2 17 (34) 
N3 24 (48) 
ND 1 (2) 
NC 2 (4) 
Liver metastases  
No 26 (52) 
Limited 5 (10) 
Diffuse 9 (18) 
ND 9 (18) 
NC 1 (2) 
Aspect tumor  
Homogeneous 16 (32) 
Heterogeneous 29 (58) 
ND 2 (4) 
NC 3 (6) 
Tumor border*  
Smooth 5 (10) 
Lobulated 23 (46) 
Spiculated 26 (52) 
Internal characteristics*  
Calcification 6 (12) 
Necrosis 10 (20) 
Air bronchogram 10 (20) 
Cavitation 1 (2) 
Pleural invasion 15 (30) 
Notching 0 (0) 
External characteristics*  
Groundglass 12 (24) 
Bubble lucencies 0 (0) 
Open bronchus sign 0 (0) 
Pleural tag 7 (14) 
Distal mucus plug 1 (2) 
Distal atelectasis 6 (12) 
Pleural fluid 3 (6) 
Satellite lesions 18 (36) 
Emphysema 24 (48) 
Abbreviations: LCNEC  large cell neuroendocrine carcinoma, ND Not deter-
minable (could not be determined by 2/3 radiologists), NC No consensus (no 
majority (2/3) for one answer (3/3 for tumor location)), LLL  left lower lobe, 
LUL  left upper lobe, RLL  right lower lobe, RML  right middle lobe, 
RUL  right upper lobe. 
* Multiple answers possible for each scan. 
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B, Supplemental figure E). The area under the operating characteristics 
curve (AUC) for this model was 0.84 (95% confidence interval (CI) 0.76 
– 0.92) and for the external validation set of SCLC and NSCLC 0.84 (95% 
CI 0.77-0.92). The validated model was applied to the scans of pSCLC- 
like and pNSCLC-like LCNEC patients, which resulted in an AUC of 
0.58 (95% CI 0.29 – 0.86) (Supplemental figures F-H). According to the 
model 7/36 LCNEC were allocated to the SCLC category and 29/36 to 
the NSCLC category. In the subtypes, 4/28 scans of pSCLC-like LCNEC 
were allocated to the SCLC category and 5/8 pNSCLC-like LCNEC were 
allocated to the NSCLC category (Fig. 2). The PPV of a SCLC category 
outcome of the model to be a pSCLC-like LCNEC was therefore 57%. The 
PPV of a NSCLC category outcome of the model to be pNSCLC-like 
LCNEC was only 17%. 
4. Discussion 
In this study, we have investigated whether pSCLC-like and pNSCLC- 
like stage IV LCNEC could be distinguished on CT-scans based on im-
aging interpretation, semantic features or a radiomics signature. Path-
ological diagnosis of LCNEC is complicated and preferably, surgical 
resected tumor tissue is used [3]. However, patients with LCNEC often 
present with disseminated disease and the diagnosis is generally based 
on small tumor biopsies, that are not always conclusive regarding the 
histological subtype of the tumor, requiring larger and/or repeated bi-
opsies [1]. Here, we tried to find less invasive alternatives to subclassify 
LCNEC. The radiomics signature trained on scans of SCLC and NSCLC 
patients was able to identify SCLC and NSCLC in an external validation 
set. However, pSCLC-like and pNSCLC-like LCNEC could not be sepa-
rated by this signature. The subclassification between molecular LCNEC 
subtypes could neither be made based on imaging interpretation or 
semantic features. Moreover, LCNEC cases showed features of both SCLC 
and NSCLC, showing that LCNEC is a separate entity. 
In this study, experienced pulmonary oncologists and chest radiol-
ogists could fairly differentiate between SCLC and NSCLC based features 
provided by CT-scans. However, no difference between pSCLC-like and 
pNSCLC-like LCNEC could be identified. So far, only one study of 8 
LCNEC patients found 3/4 pSCLC-like LCNEC to be located central and 
3/4 pNSCLC-like LCNEC to be located peripheral [10]. Based on the 
results of our study, in case the interpretation of a CT-scan of stage IV 
lung cancer by consensus is ‘small cell-like’, pathologic investigations 
will probably confirm SCLC morphology or pSCLC-like LCNEC. In 
contrast, if the interpretation is ‘non-small cell-like’, pathology can still 
reveal SCLC or pSCLC-like LCNEC, and no clinical consequences should 
be imposed. 
Semantic features in a cohort of 50 stage IV LCNEC patients have not 
been investigated previously. The percentages of semantic features we 
found are in general comparable to those of smaller series including 
mainly stage I-III LCNEC (Table 2) [11–15,19]. Most semantic features 
in LCNEC were identified in percentages in between percentages pre-
viously described for SCLC and NSCLC. For example, the percentage of 
central LCNEC lesions was in between that of SCLC and NSCLC and 
similar patterns were seen for pleural tags, distal atelectases, liver me-
tastases and N-stage [11,12,14,18]. This indicates that LCNEC is a 
unique disease with characteristics of both SCLC and NSCLC. 
We created an accurate radiomics signature that was able to classify 
SCLC and NSCLC based on CT-scans. To the best of our knowledge, only 
two studies, both without external validation, have reported on the 
separation of SCLC and NSCLC, constructing signatures with an AUC of 
0.74 (95% CI 0.68-0.80) and >0.60, respectively [8,9]. Despite the good 
performance of our signature in the SCLC vs. NSCLC external validation 
Fig. 2. Clinical interpretation of CT-scans by pulmonary oncologists and radiologists, probability score of radiomics signature and semantic features of subtypes of 
stage IV large cell neuroendocrine carcinoma and control scans of small cell lung carcinoma and non-small cell lung carcinoma. *Radiomics probability: Close to 
0 more likely to be SCLC, close to 1 more likely to be NSCLC. Abbreviations: SCLC  small cell lung carcinoma, NSCLC  non-small cell lung carcinoma, 
LCNEC  large cell neuroendocrine carcinoma, pSCLC-like  pathological SCLC-like, pNSCLC-like  pathological NSCLC-like, iSCLC-like  imaging SCLC-like, 
iNSCLC-like  imaging NSCLC-like, GGO  ground glass opacities, N-stage  nodal stage. 
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set, our model was unable to separate pSCLC-like and pNSCLC-like 
LCNEC. This indicates that pSCLC-like LCNEC and SCLC as well as 
pNSCLC-like LCNEC and NSCLC have different quantitative imaging 
features. This further adds to the unique characteristics of LCNEC 
compared to both SCLC and NSCLC. 
This study has several limitations. First, a limited number of CT-scans 
of stage IV LCNEC patients was available for this study due to the rarity 
of LCNEC and various technical and regulatory bottlenecks to obtain 
scans from multiple hospitals. Furthermore, development of the radio-
mics model was complicated by quite high heterogeneity in the applied 
scanning protocol, probably due to the long time frame in which the 
examinations were performed (2003-2018) and the large number of 
hospitals included from all over the Netherlands. To correct for inter- 
scanner model, acquisition protocol and reconstruction settings varia-
tion, we used the ComBat statistical harmonization technique available 
for multicenter imaging studies before developing the radiomics signa-
ture [20–22]. 
In conclusion, LCNEC has radiological characteristics of both SCLC 
and NSCLC, but these characteristics do not correlate with pSCLC-like 
and pNSCLC-like LCNEC subtypes based on imaging interpretation by 
pulmonary oncologists and radiologists, semantic features or a radio-
mics signature designed to differentiate between SCLC and NSCLC. Most 
LCNEC were classified by clinicians and radiomics as NSCLC-like despite 
SCLC-like molecular characteristics, highlighting LCNEC as a unique 
tumor entity. 
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